Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2016 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling, with the three conditions met. Let's analyze the transcript. The question asks: Does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look for management's own words conveying that they are speaking about counterparties' business as part of their own, that they are already inside that growth, and that the counterparties' trajectory is early and large relative to the company. Let's scan the transcript for any such narrative. The call covers DuPont's Q1 2016 earnings. Management discusses various segments: Agriculture, Nutrition & Health, Industrial Biosciences, Protection Solutions, Electronics & Communications, Performance Materials. They talk about cost savings, working capital, merger with Dow, etc. Key points: Ed Breen talks about overall performance, Ag strength, Nutrition & Health growth with examples like Supero, Greek yogurts in China, probiotics up 30%. He mentions "new products contributed to our growth" but not specifically about counterparties' own expansion. He talks about cost savings, working capital, CapEx, merger progress. Nick Fanandakis discusses financials, segment results, currency, tax, cost savings. He mentions "developing markets" sales up 5% driven by Agriculture and Nutrition & Health in Europe and Asia Pacific, but not specific counterparties' trajectories. Jim Collins discusses Agriculture in detail. He talks about market conditions, farmer economics, inventory, pricing, volumes. He mentions "stronger sunflower sales in Europe based on the performance of our newest products." He talks about pipeline: Zorvec fungicide, Leptra insect protected corn hybrids in Brazil, Roundup Ready 2 Xtend soybeans, CRISPR-Cas.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.